Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Virchows Archiv : an International Journal of Pathology|June 22, 2005
Inter-laboratory validation of PCR-based detection of Mycobacterium tuberculosis in formalin-fixed, paraffin-embedded tissuesChristiane Schewe, Torsten Goldmann, Marianne Grosser, et al.
Scientific Reports|October 6, 2022
Integrated radiogenomics analyses allow for subtype classification and improved outcome prognosis of patients with locally advanced HNSCCAsier Rabasco Meneghetti, Alex Zwanenburg, Annett Linge, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 16, 2022
Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapyShivaprasad Patil, Annett Linge, Marianne Grosser, et al.
The Journal of Molecular Diagnostics : JMD|April 6, 2020
Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell CarcinomaStefan Schmidt, Annett Linge, Marianne Grosser, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 18, 2023
The value of subcutaneous xenografts for individualised radiotherapy in HNSCC: Robust gene signature correlates with radiotherapy outcome in patients and xenograftsAnnett Linge, Shivaprasad Patil, Marianne Grosser, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 9, 2022
Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapyShivaprasad Patil, Bouchra Tawk, Marianne Grosser, et al.
Cancers|June 24, 2022
A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORTShivaprasad Patil, Annett Linge, Hannah Hiepe, et al.
Pageof 2